Stocklytics Platform
Asset logo for symbol AUPH
Aurinia Pharmaceuticals
AUPH77
$8.43arrow_drop_up2.06%$0.16
Asset logo for symbol AUPH
AUPH77

$8.43

arrow_drop_up2.06%

Performance History

Chart placeholder
Key Stats
Open$7.95
Prev. Close$8.01
EPS-0.15
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range7.87
8.14
52 Week Range4.71
10.05
Ratios
EPS-0.15

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Aurinia Pharmaceuticals (AUPH)

Aurinia Pharmaceuticals Inc. (AUPH) is a pharmaceutical company focused on developing and commercializing therapies to treat various diseases. The company's lead product candidate is voclosporin, which is being developed for the treatment of lupus nephritis (LN), a chronic inflammatory kidney disease. LN is a serious and potentially life-threatening complication of systemic lupus erythematosus (SLE), an autoimmune disease. Currently, there are limited treatment options available for LN, and there is a significant unmet need for safe and effective therapies.
Aurinia Pharmaceuticals Inc. recently announced positive results from its Phase 3 clinical trial of voclosporin in patients with LN. The trial met its primary endpoint, demonstrating a statistically significant improvement in renal response rates compared to standard of care. These results are highly encouraging, as they suggest that voclosporin has the potential to become a new standard of care for patients with LN.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Peter S. Greenleaf M.B.A.
Headquarters
Victoria
Employees
300
Exchange
NASDAQ
add Aurinia Pharmaceuticals  to watchlist

Keep an eye on Aurinia Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Aurinia Pharmaceuticals 's (AUPH) price per share?

The current price per share for Aurinia Pharmaceuticals (AUPH) is $8.44. The stock has seen a price change of $0.17 recently, indicating a 2.06% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Aurinia Pharmaceuticals (AUPH)?

For Aurinia Pharmaceuticals (AUPH), the 52-week high is $10.05, which is 19.12% from the current price. The 52-week low is $4.71, the current price is 79.13% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Aurinia Pharmaceuticals (AUPH) a growth stock?

Aurinia Pharmaceuticals (AUPH) has shown an average price growth of -7.23% over the past three years. It has received a score of 50 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Aurinia Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Aurinia Pharmaceuticals (AUPH) stock price performance year to date (YTD)?

As of the latest data, Aurinia Pharmaceuticals (AUPH) has a year-to-date price change of -3.47%. Over the past month, the stock has experienced a price change of 17.67%. Over the last three months, the change has been 31.21%. Over the past six months, the figure is 45.97%. Looking at a longer horizon, the five-year price change stands at 38.54%.
help

Is Aurinia Pharmaceuticals (AUPH) a profitable company?

Aurinia Pharmaceuticals (AUPH) has a net income of -$78.02M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 91.94% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 17.33% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $175.51M, with a revenue growth rate of 30.95%, providing insight into the company's sales performance and growth. The gross profit is $161.36M. Operating income is noted at -$91.69M. Furthermore, the EBITDA is $495K.
help

What is the market capitalization of Aurinia Pharmaceuticals (AUPH)?

Aurinia Pharmaceuticals (AUPH) has a market capitalization of $1.19B. The average daily trading volume is 8.4, indicating the stock's liquidity and investor engagement.

News

Take Your Investments to a Whole New Level